Clinical Trials List
2025-10-01 - 2029-12-31
Recruiting7
ICD-10C00.0
Malignant neoplasm of external upper lip
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9140.0
Malignant neoplasm of upper lip, vermilion border
-
-
Trial Applicant
Johnson & Johnson
-
Sponsor
-
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/05/13
Investigators and Locations
Co-Principal Investigator
- 王閔宏 Division of Hematology & Oncology
- Tsung-Jang Yeh Division of Hematology & Oncology
- Jeng-Shiun Du Division of Hematology & Oncology
- 許瑞峰 Division of Hematology & Oncology
- 謝子禹 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Mu-Hsin Chang Division of Hematology & Oncology
- Tien-Hua Chen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Ming-Yu Lien Division of Hematology & Oncology
- Ching-Chan Lin Division of Hematology & Oncology
- 陳珈妤 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 劉奕廷
- Shang-Yin Wu Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 黃彥霖 Division of Others
- RUEY-LONG HONG Division of Hematology & Oncology
- 廖斌志 Division of Hematology & Oncology
- 王郁棻 Division of Radiology
- 楊明翰 Division of Hematology & Oncology
- HUAI-CHENG HUANG Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Study Contacts
- -
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
25 participants
-
Global
500 participants
